Immunome
IMNM | NASDAQ
$17.61
-$1.16 (-6.18%)
At close: Nov 16, 2026, 4:00 PM ET
$17.69
+$0.08 (+0.45%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Immunome Company Profile
Company profile explainedCompany Profile
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Key Executives
| Name | Position |
|---|---|
| Clay Siegall | Chairman, President & Chief Executive Officer |
| Max Rosett | Chief Financial Officer |
| Sandra G. Stoneman | Chief Legal Officer, General Counsel & Corporate Secretary |
| Jack Higgins | Chief Scientific Officer |
| Kinney Horn | Chief Business Officer |
| Philip Tsai | Chief Technical Officer |
| Robert J. Lechleider | Chief Medical Officer |
| Roee Shahar | Executive Vice President of Commercial |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 05, 2026 | 8-K | Current Report |
| Sep 15, 2026 | 4 | Filing |
| Sep 11, 2026 | 144 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 12, 2026 | 4 | Filing |
| Aug 12, 2026 | 144 | Filing |
| Aug 11, 2026 | S-8 | Filing |
| Aug 11, 2026 | 10-Q | Quarterly Report |
Immunome
| Country | United States |
| IPO Date | Oct 2, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 247 |
| CEO | Clay Siegall |
Contact Details
18702 North Creek Parkway Bothell,
Washington 98011 United States
Stock Details
| Ticker Symbol | IMNM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001472012 |
| CUSIP Number | 45257U108 |
| ISIN Number | US45257U1088 |
| SIC Code | 2834 |
Recent News
- 6 days ago / benzinga.comImmunome Analysts Cut Their Forecasts After Q3 Results
- 10 days ago / businesswire.comImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 13 days ago / zacks.comWall Street Analysts Predict a 73.95% Upside in Immunome (IMNM): Here's What You Should Know
- 13 days ago / zacks.com4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
- 15 days ago / businesswire.comImmunome to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
- 18 days ago / businesswire.comImmunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
- 22 days ago / businesswire.comImmunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026
- 2 months ago / businesswire.comImmunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors
- 3 months ago / businesswire.comImmunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- 3 months ago / marketbeat.comargenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing
Add to Watchlist
Select watchlists to add or remove IMNM